Patents by Inventor Aloka B. Bandara

Aloka B. Bandara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NDUFS2 SUBUNIT KNOCKOUT HUMAN CELL LINE
    Publication number: 20220299500
    Abstract: Disclosed herein is a recombinant human cell line that does not express functional endogenous NADH dehydrogenase [ubiquinone] iron-sulfur protein 2 (NDUFS2). This knockout cell line can be used to advance the basic understanding of the NDUFS2 protein subunit in overall complex I assembly and function. Furthermore, this cell line can be used to test therapeutic agents to fix or bypass the dysfunctional complex I.
    Type: Application
    Filed: September 30, 2020
    Publication date: September 22, 2022
    Inventors: Aloka B. BANDARA, David A. BROWN
  • Development of a live, attenuated, recombinant vaccine for Brucellosis
    Patent number: 7364745
    Abstract: A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for the prevention or treatment of Brucellosis. Prior exposure to the Brucella species is identified by detecting a genetic sequence for carboxyl-terminal (i.e. tail-specific) protease activity in a biological sample.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: April 29, 2008
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Aloka B. Bandara, Stephen M. Boyle, Nammalwar Sriranganathan, Gerhardt G. Schurig